Impact of Colchicine in Hospitalized Colombian Patients With COVID-19
Status:
Not yet recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
This is a phase IIIa, prospective, open-label, randomized, parallel-group study designed to
evaluate the efficacy and safety of oral colchicine plus standard therapy versus standard
therapy in the clinical course of SARS-CoV-2 infection, in a population group with moderate
COVID-19 compromise and requiring hospitalization.Aproximately 120 subjects meeting all
inclusion and not inclusion criteria will be randomized to receive either Colchicine plus
standard treatment or only standard treatment for 15 days